Skip to main content
Equibles
LSTA logo

LSTA · Lisata Therapeutics, Inc. · Metrics

Track LSTA — free

Use LSTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LSTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.00 -0.01 (-0.91%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current business plan and existing capital resources, management has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of twelve months from the date of issuance of the accompanying consolidated financial statements.”
View the 10-Q filed Aug 6, 2026
Market Cap
$8.97M
Shares
9.01M
Volume · Oct 23 45.56K Avg daily vol (3M) 295.64K

LSTA metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.00
Market cap
$8.97M

Price action

20 metrics
Price change (1W)
-3.3%
Price change (30D)
-33.6%
Price change (3M)
-40.4%
Price change (6M)
-68.9%
Price change (YTD)
-46.5%
Price change (1Y)
-57.6%
Trailing year
Price change (5Y)
—
52-week high
$5.04
52-week low
$0.99
Change from 52-week high
-80.2%
Change from 52-week low
+0.6%
Annualized volatility
130.5%
Annualized volatility (3M)
137.0%
Beta
0.8
RSI (14D)
33.9
Price vs SMA 50
-28.9%
Price vs SMA 200
-67.0%
Avg volume (3M)
295,636
Relative volume
0.2
Average dollar volume
$449,516

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.01M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-14.7×
EV / EBITDA
—
EV / EBIT
—
P / sales
89.7×
reciprocal yield 1.1%
P / book
1.1
reciprocal yield 91.9%
FCF yield
-137.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-162.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
39.5×
reciprocal yield 2.5%
EV / revenue historical average (5Y)
39.5×
reciprocal yield 2.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-06

Profitability

9 metrics
Gross margin
—
Operating margin
-16,428.0%
Trailing 12 months
Net margin
-14,621.0%
Gross profit (TTM)
$2.77M
Operating profit (TTM)
−$16.43M
Net income (TTM)
−$14.62M
Trailing 12 months
Diluted EPS (TTM)
$-1.64
FCF margin
-12,323.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.01
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.84
EBITDA per diluted share (TTM)
$-1.83
Net income per diluted share (TTM)
$-1.64
Operating cash flow per diluted share (TTM)
$-1.38
Free cash flow per diluted share (TTM)
$-1.38
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.55
Stock compensation per diluted share (TTM)
—
Book value per share
$1.68

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$100,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-177.4%
Return on assets
-132.6%
Debt / equity
0.0
Current ratio
3.7
EBITDA (TTM)
−$16.36M
Free cash flow (TTM)
−$12.32M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$10.44M
Latest balance sheet
Cash & equivalents
$10.44M
Total assets
$11.03M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$12.32M
Capital expenditures (TTM)
$0
R&D (TTM)
$4.88M
SG&A (TTM)
$12.09M
Stock compensation (TTM)
$1.03M
R&D / revenue
4,882.0%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
33
13F filer change QoQ
-3
Institutional ownership
13.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
6.2%
Private-fund adviser ownership
3.8%
Active holders' share change QoQ
-24.4%
Holder tenure
3.6
Price vs estimated holder cost
-12.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.7%

Short interest

3 metrics
Short interest
0.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
28 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 320017 CUSIP 128058302 13F (30d) 4 filings 4 filers Visit website Investor relations